
Medicamen Biotech Ltd Upgraded to Sell Amid Mixed Technicals and Weak Financials
2026-05-06 08:10:38Medicamen Biotech Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook despite ongoing financial challenges. The change, effective from 5 May 2026, is driven primarily by an improvement in technical indicators, while valuation and financial trends continue to present a mixed picture for investors.
Read full news article
Medicamen Biotech Ltd is Rated Strong Sell
2026-05-05 10:10:17Medicamen Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.
Read full news article
Medicamen Biotech Ltd is Rated Strong Sell
2026-04-24 10:10:31Medicamen Biotech Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 February 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 24 April 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Medicamen Biotech Ltd Valuation Shifts Signal Changing Market Sentiment
2026-04-23 08:00:58Medicamen Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair rating. Despite a recent uptick in its share price, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside subdued returns on capital, have raised concerns among investors and analysts alike.
Read full news article
Medicamen Biotech Ltd is Rated Strong Sell
2026-04-13 10:10:32Medicamen Biotech Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 14 February 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are based on the company’s current position as of 13 April 2026, providing investors with the latest comprehensive view of the stock’s performance and prospects.
Read full news article
Medicamen Biotech Ltd is Rated Strong Sell
2026-04-02 10:10:29Medicamen Biotech Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 14 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and technical outlook.
Read full news article
Medicamen Biotech Ltd Falls to 52-Week Low of Rs 225 as Sell-Off Deepens
2026-03-30 11:46:12For the second consecutive session, Medicamen Biotech Ltd has seen its share price slide further, hitting a fresh 52-week low of Rs 225 on 30 Mar 2026. This decline extends a recent losing streak that has erased nearly 10% of its value over two days, underscoring persistent selling pressure amid a challenging market backdrop.
Read full news article
Medicamen Biotech Ltd Falls to 52-Week Low of Rs 234.35 as Sell-Off Deepens
2026-03-27 15:55:50A sharp decline in Medicamen Biotech Ltd has pushed the stock to a fresh 52-week low of Rs 234.35 on 27 Mar 2026, marking a significant 47.95% drop over the past year. This downturn comes amid broader market weakness and persistent underperformance relative to benchmarks and peers.
Read full news article
Five Consecutive Losses Push Medicamen Biotech Ltd to a New 52-Week Low
2026-03-23 11:00:31For the fifth consecutive session, Medicamen Biotech Ltd has closed lower, hitting a fresh 52-week low of Rs 243.25 on 23 Mar 2026. This decline comes amid a broader sector downturn but marks a significant underperformance relative to the market and peers.
Read full news articleCorporate Actions
No Upcoming Board Meetings
Medicamen Biotech Ltd has declared 10% dividend, ex-date: 19 Sep 25
No Splits history available
No Bonus history available
No Rights history available






